HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Endocannabinoid 1 and 2 (CB(1); CB(2)) receptor agonists affect negatively cow luteal function in vitro.

Abstract
Thirty to 40% of pregnancies are lost during the first third of pregnancy, which has been hypothesized to be due to inadequate progesterone secretion by the corpus luteum. Loss of luteal progesterone secretion during the estrous cycle is via uterine secretion of prostaglandin F(2)alpha (PGF(2)alpha). Cow luteal tissue secretion of prostaglandins (PG) E (PGE(1)+PGE(2)) and PGF(2)alpha are derived from precursors in membrane phospholipids. Cow luteal tissue secretion of PGE and PGF(2)alpha increased linearly with time in culture with the PGE: ratio being 1:1. PGE(1) or PGE(2) are luteotropic in cows and ewes and antiluteolytic in vitro and in vivo in ewes. Endocannabinoids are also derived from phospholipids and are associated with infertility, presumably by reducing implantation; however, effects of endocannabinoids on luteal function have not been addressed. The objective of this experiment was to determine the effects of endocannabinoid type 1 and 2 receptor agonists and receptor antagonists or a fatty acid amide hydrolase (FAAH; catabolizes endocannabinoids) inhibitor, PGE(1), or PGF(2)alpha on bovine luteal secretion of progesterone, PGE, and PGF(2)alphain vitro. PGE and PGF(2)alpha was increased (P< or =0.05) with time in culture, while progesterone did not change (P> or =0.05) with time in vehicle-treated luteal slices in vitro. Progesterone was increased (P< or =0.05) by PGE(1) and decreased (P< or =0.05) by PGF(2)alpha, CB(1) or CB(2) receptor agonists, or a FAAH inhibitor. Both PGE and PGF(2)alpha were decreased (P< or =0.05) by CB(1) or CB(2) receptor agonists or a FAAH inhibitor when compared to vehicle controls. It is concluded that endocannabinoid receptor agonists negatively affect cow luteal function in vitro and that the corpus luteum may also be a site for endocannabinoid decreased fertility as well as a reduction in implantation.
AuthorsY S Weems, A W Lewis, D A Neuendorff, R D Randel, C W Weems
JournalProstaglandins & other lipid mediators (Prostaglandins Other Lipid Mediat) Vol. 90 Issue 3-4 Pg. 89-93 (Dec 2009) ISSN: 1098-8823 [Print] United States
PMID19765667 (Publication Type: Journal Article)
Chemical References
  • Arachidonic Acids
  • Indoles
  • Organophosphonates
  • Piperidines
  • Pyrazoles
  • Pyrrolidines
  • Receptor, Cannabinoid, CB1
  • Receptor, Cannabinoid, CB2
  • arachidonylcyclopropylamide
  • methyl arachidonylfluorophosphonate
  • AM 251
  • Progesterone
  • Dinoprost
  • Adenine
  • Adenosine
  • Dinoprostone
  • galidesivir
  • iodopravadoline
Topics
  • Adenine (analogs & derivatives, pharmacology)
  • Adenosine (analogs & derivatives)
  • Animals
  • Arachidonic Acids (pharmacology)
  • Cattle (physiology)
  • Corpus Luteum (drug effects, physiology)
  • Dinoprost (physiology)
  • Dinoprostone (physiology)
  • Female
  • In Vitro Techniques
  • Indoles (pharmacology)
  • Organophosphonates (pharmacology)
  • Piperidines (pharmacology)
  • Pregnancy
  • Progesterone (blood)
  • Pyrazoles (pharmacology)
  • Pyrrolidines (pharmacology)
  • Random Allocation
  • Receptor, Cannabinoid, CB1 (agonists)
  • Receptor, Cannabinoid, CB2 (agonists)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: